Patient with polymorbid pathology. Possibilities of therapy with monoclonal antibodies

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


With the widespread increase in the number of patients with allergic pathology, doctors in clinical practice increasingly have to observe the simultaneous development of several nosological forms in the same patient. Frequent occurrence of a combination of lesions of the skin and respiratory tract in patients with atopy (atopic dermatitis, allergic rhinitis, and atopic bronchial asthma) is traditionally considered within the framework of comorbidity and suggests a number of therapeutic interventions given the similarity of the pathogenesis. However, phenotypic or endotypic differences exist between patients (e.g., triggers, age, persistence of manifestations, degree and type of inflammation, severity of symptoms, and response to treatment), for which it is more correct to use the term multimorbidity. The strategy of precision medicine for patients with several immune-mediated diseases should focus on identifying not only the general features of the disease, but also the pathogenetic mechanisms in the target organs. Because of these differences, the sensitivity to therapeutic interventions by target organs can vary. Herein, a clinical case of a patient with comorbid pathology ― chronic spontaneous urticaria, allergic rhinitis, and bronchial asthma ―was analyzed. Respiratory manifestations (rhinitis and asthma) were mild to severe. Chronic urticaria had the most severe disease course and resistant to antihistamines, which are considered first and second lines of drugs according to federal and international clinical guidelines that required the use of monoclonal antibodies. Anti-IgE therapy with omalizumab had a rapid and complete effect on urticaria symptoms, but respiratory symptoms were less responsive to treatment. In patients with multimorbid pathology, therapy should be individualized in terms of targeted drugs and their dosage.

Full Text

Restricted Access

About the authors

Natalia G. Astafyeva

Saratov State Medical University n.a. V.I. Razumovskiy” of the Ministry of Healthcare of the Russian Federation

Author for correspondence.
ORCID iD: 0000-0002-7691-4584
SPIN-code: 9941-7013
Scopus Author ID: 6506637441
ResearcherId: AAI-3342-2020

MD, PhD, Doctor of Medical Sciences, professor

Russian Federation, 22 Proviantskaya str., 410028, Saratov

Ekaterina N. Udovichenko

Saratov State Medical University n.a. V.I. Razumovskiy” of the Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0001-8108-782X
SPIN-code: 3026-5331

MD, Cand. Sci. (Med.), Assistant Professor

Russian Federation, 22 Proviantskaya str., 410028, Saratov


  1. Pawankar R, Canonica GW, Holgate ST, Lockey RF, editors. WAO White Book on Allergy. Copyright 2011 World Allergy Organization. Available from:
  2. Shirinsky VS, Shirinsky IV. Comorbid diseases-an actual problem of clinical medicine. Siberian Medical Journal. 2014;29(1):7–12. (In Russ).
  3. Lazebnik LB. Aging and polymorbidity. Consilium medicum. 2005;7(12):993–996. (In Russ).
  4. Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis. 1970;23(7):455–468. doi: 10.1016/0021-9681(70)90054-8
  5. Wedback ЕH, Eriksson NE, Movérare R, Malcus I. Seasonal non-allergic rhinitis (SNAR) – a new disease entity? A clinical and immunological comparison between SNAR, seasonal allergic rhinitis and persistent non-allergic rhinitis. Rhinology. 2005;43(2):86–92.
  6. Hellings PW, Fokkens WJ, Bachert C, et al. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement. Allergy. 2017;72(9):1297–1305. doi: 10.1111/all.13162
  7. Bousquet J, Schunemann HJ, Fonseca J, et al. MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. Allergy. 2015;70(11):1372–1392. doi: 10.1111/all.12686
  8. Vadasz Z, Kessel A, Hershko AY, et al. Seasonal exacerbation of asthma is frequently associated with recurrent episodes of acute urticaria. Int Arch Allergy Immunol. 2016;169(4):263–266. doi: 10.1159/000446183
  9. Asero R, Madonini E. Bronchial hyperresponsiveness is a common feature in patients with chronic urticaria. J Investig Allergol Clin Immunol. 2006;16(1):19–23.
  10. Isik AR, Karakaya G, Celikel S, et al. Association between asthma, rhinitis, and NSAID hypersensitivity in chronic urticaria patients and prevalence rates. Int Arch Allergy Immunol. 2009;150(3):299–306. doi: 10.1159/000222683
  11. Vollono L, Piccolo A, Lanna C, et al. Omalizumab for chronic spontaneous urticaria in “complex” patients: data from real-life clinical practice. Drug Des Devel Ther. 2019;6:3181–3186. doi: 10.2147/DDDT.S214307
  12. Greaves M, Sabroe R. PL007 Urticaria and autoimmunity. Journal of the European Academy of Dermatology and Venereology. 1997;9:S2. doi: 10.1016/s0926-9959(97)88838-1
  13. Fricke J, Ávila G, Keller T, et al. Prevalence of chronic urticaria in children and adults across the globe: Systematic review with metaanalysis. Allergy. 2020;75(2):423–432. doi: 10.1111/all.14037
  14. Kozel MA, Sabroe R. Chronic urticaria: aetiology, management and current and future treatment options. Drugs. 2004;64(22): 2515–2536. doi: 10.2165/00003495-200464220-00003
  15. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69(7):868–887. doi: 10.1111/all.12313
  16. Konstantinou GN, Asero R, Ferrer M, et al. EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria. Allergy. 2012;68(1):27–36. doi: 10.1111/all.12056
  17. Kolkhir P, Metz M, Altrichter S, Maurer M. Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: A systematic review. Allergy. 2017;72(10):1440–1460. doi: 10.1111/all.13182
  18. Kolkhir P, Church M, Weller K, et al. Autoimmune chronic spontaneous urticaria: What we know and what we do not know. Allergy Clin Immunol. 2017;139(6):1772–1781.e1. doi: 10.1016/j.jaci.2016.08.050
  19. Kaplan AP, Greaves M. Pathogenesis of chronic urticaria. Clin Exp Allergy. 2009;39(6):777–787. doi: 10.1111/j.1365-2222.2009.03256.x
  20. Altrichter S, Peter H, Pisarevskaja D, et al. IgE mediated autoallergy against thyroid peroxidase – a novel pathomechanism of chronic spontaneous urticaria? PLoS One. 2011;6(4):e14794. doi: 10.1371/journal.pone.0014794
  21. Staubach P, Vonend A, Burow G, et al. Patients with chronic urticaria exhibit increased rates of sensitisation to Candida albicans, but not to common moulds. Mycoses. 2009;52(4):334–338. doi: 10.1111/j.1439-0507.2008.01601.x
  22. Metz M, Maurer M. Omalizumab in chronic urticaria. Curr Opin Allergy Clin Immunol. 2012;12(4):406–411. doi: 10.1097/aci.0b013e328355365a
  23. Tharp MD, Bernstein JA, Kavati A, et al. Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria. JAMA Dermatology. 2019;1(155):29–38. doi: 10.1001/jamadermatol.2018.3447
  24. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393–1414. doi: 10.1111/all.13397
  25. Federal clinical guidelines of the Federal State Budgetary Institution GNCDC. (In Russ). Available from:
  26. Gericke J, Metz M, Ohanyan T, et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. J Allergy Clin Immunol. 2017;139(3):1059–1061. doi: 10.1016/j.jaci.2016.07.047
  27. Arnau AM, Santiago VA, Tomás BJ, et al. Therapeutic strategy according to differences in response to omalizumab in patients with chronic spontaneous urticaria. J Investig Allergol Clin Immunol. 2019;29(5):338–348. doi: 10.18176/jiaci.0323
  28. Vadasz Z, Tal Y, Rotem M, et al. Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients. J Allergy Clin Immunol Pract. 2017;5(6):1743–1745. doi: 10.1016/j.jaip.2017.08.035
  29. Ren Z, Wedner HJ. Long term efficacy of Omalizumab for patients with refractory chronic urticaria and angioedema. Journal of Allergy and Clinical Immunology. 2018;141(2):AB52. doi: 10.1016/j.jaci.2017.12.167
  30. Asero R, Canonica GW, Cristaudo A, et al. Critical appraisal of the unmet needs in the treatment of chronic spontaneous urticaria with omalizumab: an Italian perspective. Curr Opin Allergy Clin Immunol. 2017;17(6):453–459. doi: 10.1097/aci.0000000000000404.

Supplementary files

There are no supplementary files to display.

Copyright © Pharmarus Print Media, 2021

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies